抗风湿性关节炎患者中耐火性皮肤病的Adalimumab的葡萄糖皮质类药物节约作用:一系列病例
Shin-Ichiro Ohmura1, Naomi Morishita2, Haruka Yonezawa1
1Department of Rheumatology, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan.
Modern rheumatology case reports
|December 10, 2024
概括
艾达利穆马布 (ADA) 在治疗类风湿性关节炎 (RA) 患者的皮肤质 (PG) 方面表现有前途. 这项研究表明,ADA可能会减少对葡萄糖皮质类药物的需要,以控制与RA相关的耐火性PG.
科学领域:
- 类风湿病学 类风湿病学
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
背景情况:
- 皮肤性 (PG) 是一种罕见的,痛苦的性皮肤病,缺乏治疗指南.
- 系统性治疗对于PG是常见的,用TNF抑制剂阿达利穆马布 (ADA) 治疗,最近在日本批准用于耐火病例.
- 对于患有全身性类风湿性疾病 (SRD),如类风湿性关节炎 (RA) 的PG患者,ADA的疗效以及其节糖皮质激素的潜力仍然不清楚.
研究的目的:
- 评估阿达利穆马布 (ADA) 在治疗风湿性关节炎 (RA) 患者的耐火性皮肤病 (PG) 的有效性.
- 为了研究ADA在这个患者群体中的潜在的葡萄糖皮质醇节约作用.
主要方法:
- 关于两名患有类风湿性关节炎 (RA) 和抗葡萄糖皮质类药物耐药性皮肤病 (PG) 的患者的病例报告.
- 进行的治疗包括阿达利穆马布 (ADA).
- 监测了临床结果和葡萄糖皮质醇剂量.
主要成果:
- 这两位患有与RA相关的耐火性PG的患者都表现出阿达利姆巴 (ADA) 治疗的成功结果.
- 在这些情况下,阿达利穆马布 (ADA) 似乎减少了对葡萄糖皮质类药物治疗的需求.
- 该研究强调了ADA在治疗复杂的PG病例中在风湿性疾病背景下具有潜在的益处.
结论:
- 阿达利穆马布 (ADA) 可能是患有类风湿性关节炎 (RA) 的患者皮肤质 (PG) 的有效治疗选择.
- ADA显示出一种潜在的糖皮质激素节约作用,为RA患者耐火性PG提供了有价值的治疗策略.
- 需要进一步的研究,以在更大的队列中证实这些发现.
相关概念视频
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
142
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
142
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
115
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
115
01:29Inflammatory Bowel Disease IV: Pharmacological Management
112
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
112
01:29Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119